ES2591129T3 - Tienopirimidinas - Google Patents

Tienopirimidinas Download PDF

Info

Publication number
ES2591129T3
ES2591129T3 ES13725935.4T ES13725935T ES2591129T3 ES 2591129 T3 ES2591129 T3 ES 2591129T3 ES 13725935 T ES13725935 T ES 13725935T ES 2591129 T3 ES2591129 T3 ES 2591129T3
Authority
ES
Spain
Prior art keywords
alkyl
nr6r7
group
cycloalkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13725935.4T
Other languages
English (en)
Inventor
Georg Kettschau
Florian PÜHLER
Knut Eis
Ulrich Klar
Dirk Kosemund
Detlev Sülzle
Philip Lienau
Andrea HÄGEBARTH
Ulf Bömer
Lars Wortmann
Keith Graham
Antje Margret Wengner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of ES2591129T3 publication Critical patent/ES2591129T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un compuesto de fórmula general (I): **Fórmula** en la que: R1 representa un grupo seleccionado de: -C(>=O)O-R3, -C(>=O)N(H)R3, -C(>=O)NR3R4; R2a, R2b, R2c, R2d representan, independientemente entre sí, un átomo de hidrógeno o un grupo seleccionado de: alquil C1-C3-, alcoxi C1-C3-, halo-, hidroxi-, haloalquil C1-C3-, haloalcoxi C1-C3-, ciano-, -N(H)R5, -NR5R4; R3 representa un átomo de hidrógeno o un grupo seleccionado de: alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, -(CH2)q-(cicloalquilo C3-C7), -(CH2)q-O-(cicloalquilo C3-C7), -(CH2)q-(cicloalquenilo C4-C7), -(CH2)q-O- (cicloalquenilo C4-C7), -(CH2)q-(heterocicloalquilo de 3 a 10 miembros), -(CH2)q-O-(heterocicloalquilo de 3 a 10 miembros), -(CH2)q-(heterocicloalquenilo de 4 a 10 miembros), -(CH2)q-O-(heterocicloalquenilo de 4 a 10 miembros), -(CH2)q-arilo, -(CH2)q-O-arilo, -(CH2)q-heteroarilo, -(CH2)q-O-heteroarilo; estando dicho grupo opcionalmente sustituido, una o más veces, de forma idéntica o diferente, con un sustituyente seleccionado de: halo-, hidroxi-, oxo- (O>=), ciano-, nitro-, alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, haloalquil C1-C6-, alcoxi C1-C6-, haloalcoxi C1-C6-, hidroxialquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, -(CH2)q-arilo, -(CH2)q-heteroarilo, -(CH2)q-(cicloalquilo C3-C7), -(CH2)q-(heterocicloalquilo de 3 a 10 miembros), haloalcoxi C1-C6-alquil C1-C6-, R5-O- , -C(>=O)R5, -C(>=O)O-R5, -OC(>=O)R5, -N(H)C(>=O)R5, -N(R4)C(>=O)R5, -N(H)C(>=O)NR5R4, -N(R4)C(>=O)NR5R4, -N(H)R5, -NR5R4, -C(>=O)N(H)R5, -C(>=O)NR5R4, R4-S-, R4-S(>=O), R4-S(>=O)2, -N(H)S(>=O)R4, -N(R4)S(>=O)R4, -S(>=O)N(H)R5, -S(>=O)NR5R4, -N(H)S(>=O)2R4, -N(R4)S(>=O)2R4, -S(>=O)2N(H)R5, -S(>=O)2NR5R4, -S(>=O)(>=NR5)R4, S(>=O)(>=NR4)R5, -N>=S(>=O)(R5)R4; o cuando dos sustituyentes están presentes en posición orto el uno con el otro en un anillo arilo o heteroarilo, dichos dos sustituyentes forman juntos un puente: *O(CH2)pO*, *NH(C(>=O))NH*, en los que * representa el punto de unión a dicho anillo arilo o heteroarilo; R4 representa un grupo seleccionado de: alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, haloalquil C1-C6-, hidroxialquil C1-C6-, alcoxi C1-C6-alquil C1-C6-; o NR3R4 juntos representan un grupo heterocicloalquilo de 3 a 10 miembros o un heterocicloalquenilo de 4 a 10 miembros; que está opcionalmente sustituido, una o más veces, de forma idéntica o diferente, con halo-, hidroxi-, ciano-, nitro-, alquil C1-C6-, haloalquil C1-C6-, alcoxi C1-C6-, haloalcoxi C1-C6-, hidroxialquil C1-C6-, alcoxi C1-C6- alquil C1-C6-, R6R7N-alquil C1-C6-, haloalcoxi C1-C6-alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, -(CH2)q-cicloalquilo C3-C7, -(CH2)q-arilo, -(CH2)q-heteroarilo, R5-O-, -C(>=O)R5, -C(>=O)O-R5, -OC(>=O)R5, -N(H)C(>=O)R5, -N(R4)C(>=O)R5, -N(H)C(>=O)NR6R7, -N(R5)C(>=O)NR6R7, -N(H)R5, -NR6R7, -C(>=O)N(H)R5, -C(>=O)NR6R7, R5-S-, R5-S(>=O), R5-S(>=O)2, -N(H)S(>=O)R5, -N(R5)S(>=O)R6, -S(>=O)N(H)R5, -S(>=O)NR6R7, -N(H)S(>=O)2R5, -N(R5)S(>=O)2R6, -S(>=O)2N(H)R6, -S(>=O)2NR6R7, -S(>=O)(>=NR5)R6, S(>=O)(>=NR5)R6, -N>=S(>=O)(R5)R6; en el que dichos grupos alquil C1-C6-, -(CH2)q-cicloalquilo C3-C7, -(CH2)q-arilo o -(CH2)q-heteroarilo están opcionalmente sustituidos, una o más veces, de forma idéntica o diferente, con halo-, hidroxi-, oxo- (O>=), ciano-, nitro-, alquil C1-C6-, haloalquil C1-C6-, alcoxi C1-C6-, haloalcoxi C1-C6-, hidroxialquil C1-C6-, alcoxi C1-C6-alquil C1-C6-, R6R7N-alquil C1-C6-, haloalcoxi C1-C6-alquil C1-C6-, alquenil C2-C6-, alquinil C2-C6-, R5-O-, -C(>=O)R5, -C(>=O)-R5, -OC(>=O)R5, -N(H)C(>=O)R5, -N(R4)C(>=O)R5, -N(H)C(>=O)NR6R7, -N(R5)C(>=O)NR6R7, -N(H)R5, -NR6R7, -C(>=O)N(H)R5, -C(>=O)NR6R7, R5-S-, R5-S(>=O), R5-S(>=O)2, -N(H)S(>=O)R5, -N(R5)S(>=O)R6, -S(>=O)N(H)R5, -S(>=O)NR5R6, -N(H)S(>=O)2R5, -N(R5)S(>=O)2R6, -S(>=O)2N(H)R6, -S(>=O)2NR5R6, -S(>=O)(>=NR5)R6, S(>=O)(>=NR5)R6, -N>=S(>=O)(R5)R6; R5 representa un átomo de hidrógeno, un grupo alquil C1-C6- o un cicloalquil C3-C7-; R6 representa un átomo de hidrógeno, un grupo alquil C1-C6- o un cicloalquil C3-C7-; R7 representa un átomo de hidrógeno, un grupo alquil C1-C6- o un cicloalquil C3-C7-; o NR6R7 juntos representan un grupo heterocicloalquilo de 3 a 10 miembros o un heterocicloalquenilo de 4 a 10 miembros; p representa un número entero de 1 o 2; q representa un número entero de 0, 1, 2 o 3; o un tautómero, un N-óxido, un hidrato, un solvato o una sal farmacéuticamente aceptable del mismo, o una mezcla del mismo.
ES13725935.4T 2012-05-21 2013-05-17 Tienopirimidinas Active ES2591129T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12168670 2012-05-21
EP12168670 2012-05-21
EP13153607 2013-02-01
EP13153607 2013-02-01
PCT/EP2013/060233 WO2013174744A1 (en) 2012-05-21 2013-05-17 Thienopyrimidines

Publications (1)

Publication Number Publication Date
ES2591129T3 true ES2591129T3 (es) 2016-11-25

Family

ID=48537948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13725935.4T Active ES2591129T3 (es) 2012-05-21 2013-05-17 Tienopirimidinas

Country Status (10)

Country Link
US (1) US9540392B2 (es)
EP (1) EP2852596B1 (es)
JP (1) JP6234444B2 (es)
CN (1) CN104507950B (es)
AR (1) AR091093A1 (es)
CA (1) CA2873975A1 (es)
ES (1) ES2591129T3 (es)
HK (1) HK1206723A1 (es)
UY (1) UY34817A (es)
WO (1) WO2013174744A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2852595B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
JP2016506944A (ja) 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
CN105189518A (zh) * 2013-02-01 2015-12-23 拜耳制药股份公司 取代的噻吩并吡啶和其药物用途
HK1220972A1 (zh) 2013-03-06 2017-05-19 Bayer Pharma Aktiengesellschaft 取代的噻唑并嘧啶
TW201605867A (zh) * 2013-11-20 2016-02-16 拜耳製藥公司 噻吩并嘧啶
CA2944103A1 (en) 2014-05-07 2015-11-12 Evotec International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
JP2017519737A (ja) * 2014-05-26 2017-07-20 バイエル・ファルマ・アクティエンゲゼルシャフト 置換テトラヒドロピリドチエノピリミジン
EP3149003A1 (en) * 2014-05-27 2017-04-05 Bayer Pharma Aktiengesellschaft Benzothiadiazolamines
JO3705B1 (ar) 2014-11-26 2021-01-31 Bayer Pharma AG إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية
CU20170086A7 (es) * 2014-12-19 2017-11-07 Bayer Pharma AG Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CA2982984C (en) 2015-04-20 2023-10-17 Effector Therapeutics, Inc. Inhibitors of immune checkpoint modulators for use in treating cancer and infections
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
WO2017025491A1 (en) * 2015-08-12 2017-02-16 F. Hoffmann-La Roche Ag Bace1 inhibitors
WO2017081003A1 (en) * 2015-11-12 2017-05-18 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyridinamines
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
RU2743170C2 (ru) 2016-06-01 2021-02-15 Байер Энимал Хелс Гмбх Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных
AU2017273771B2 (en) 2016-06-01 2022-09-29 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5444038A (en) 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
US6849638B2 (en) 2001-04-30 2005-02-01 Bayer Pharmaceuticals Corporation 4-amino-5,6-substituted thiopheno [2,3-d] pyrimidines, pharmaceutical compositions containing the same, and their use in the treatment or prevention of pde7b-mediated diseases and conditions
WO2005010008A1 (en) 2003-07-24 2005-02-03 Bayer Pharmaceuticals Corporation Substituted tetrahydrobenzothienopyrimidinamine compounds useful for treating hyper-proliferative disorders
US20080269238A1 (en) 2004-04-01 2008-10-30 Takeda Pharmaceutical Company Limited Thiazolopyrimidine Derivative
EP1899353A1 (en) 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
JP2007084494A (ja) 2005-09-22 2007-04-05 Oncorex Inc Ｐｉｍ−１活性阻害剤
WO2007059905A2 (en) 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
US7982035B2 (en) 2007-08-27 2011-07-19 Duquesne University Of The Holy Spirit Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof
JP5562865B2 (ja) 2007-12-17 2014-07-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｔｒｐｖ１のイミダゾロ−、オキサゾロ−、及びチアゾロピリミジン・モジュレーター
CA2722220C (en) 2008-04-30 2016-06-07 National Health Research Institutes Fused bicyclic pyrimidine compounds as aurora kinase inhibitors
AU2009286734A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
PH12012501693A1 (en) 2010-02-26 2012-11-05 Boehringer Ingelheim Int 4 - [cycloalkyloxy (hetero) arylamino] thieno [2,3 - d] pyrimidines having mnkl/mnk2 inhibiting activity for pharmaceutical compositions
EP2539344B1 (en) 2010-02-26 2014-10-15 Boehringer Ingelheim International GmbH Halogen or cyano substituted thieno[2,3-d]pyrimidines having mnk1/ mnk2 inhibiting activity for pharmaceutical compositions
BR112012021453A2 (pt) 2010-02-26 2017-02-21 Boehringer Ingelheim Int tienopirimidina, sua composição farmacêutica e seu uso
UY33241A (es) 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EP2852595B1 (en) 2012-05-21 2016-06-22 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CN104781260A (zh) 2012-09-26 2015-07-15 拜耳制药股份公司 用于治疗过度增殖性障碍的取代的吲唑-吡咯并嘧啶
US20150252047A1 (en) 2012-09-26 2015-09-10 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
JP2016506944A (ja) 2013-02-01 2016-03-07 バイエル・ファルマ・アクティエンゲゼルシャフト 置換ピラゾロピリミジニルアミノ−インダゾール
HK1220972A1 (zh) 2013-03-06 2017-05-19 Bayer Pharma Aktiengesellschaft 取代的噻唑并嘧啶

Also Published As

Publication number Publication date
JP6234444B2 (ja) 2017-11-22
EP2852596A1 (en) 2015-04-01
CN104507950A (zh) 2015-04-08
EP2852596B1 (en) 2016-06-22
JP2015517545A (ja) 2015-06-22
WO2013174744A1 (en) 2013-11-28
CA2873975A1 (en) 2013-11-28
HK1206723A1 (en) 2016-01-15
US20150133425A1 (en) 2015-05-14
CN104507950B (zh) 2017-03-22
US9540392B2 (en) 2017-01-10
UY34817A (es) 2013-12-31
AR091093A1 (es) 2015-01-14

Similar Documents

Publication Publication Date Title
ES2591129T3 (es) Tienopirimidinas
EA202091480A1 (ru) Аминоиндольные соединения, пригодные в качестве ингибиторов tlr
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
ES2421453T3 (es) Derivados de tiofenocarboxamida como ligandos del receptor EP4
AR078535A1 (es) Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras
MX391344B (es) Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
HN2010001460A (es) Derivados biciclicos de carboxamidas aza-biciclicas, su preparacion y su aplicacion terapeutica
AR098912A1 (es) Inhibidores de syk
MA38922A3 (fr) Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
CU20170160A7 (es) Derivadosde fenil-tieno(2,3-d)pirimidina- hidroxi-ésteres, un proceso para su preparación y composiciones farmacéuticas que lo contienen
AR091022A1 (es) Inhibidores del nampt
AR091786A1 (es) Inhibidores de la produccion de leucotrienos
AR089143A1 (es) Triazolopiridinas sustituidas con actividad inhibidora de ttk
AR103833A1 (es) Compuestos bicíclicos de sulfonamida cetona
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR101280A1 (es) Tieno[3,2-d]pirimidina, furo[3,2-d]pirimidina y pirrolo[3,2-d]pirimidinas útiles para el tratamiento de infecciones respiratorias por virus sincicial
EP3377066A4 (en) AMIDOSUBSTITUTED PYRIDOTRIAZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS
AR099874A1 (es) CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA
EP3389380A4 (en) SPIROCYCLIC CHINOLIZIN DERIVATIVES FOR USE AS HIV INTEGRASE INHIBITORS
PH12016502303B1 (en) Carotenoid derivative, pharmaceutically acceptable salt thereof, or pharmaceutically acceptable ester or amide thereof
AR089011A1 (es) 2h-indazoles como antagonistas del receptor ep₂
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)